Document Detail


Strategies to reverse endothelial dysfunction in diabetic nephropathy.
MedLine Citation:
PMID:  23151985     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Endothelial dysfunction underlies the basic pathophysiology of microvascular complications of diabetes. Endothelial dysfunction is associated with impaired nitric oxide (NO) availability. Since NO production is tightly regulated by endothelial nitric oxide synthase (eNOS), several therapeutic strategies have been investigated and proposed to improve eNOS bioavailability in the vasculature. The findings of Cheng et al. suggest that increased availability of eNOS may be an effective strategy in restoring endothelial function in patients with diabetic nephropathy.
Authors:
Shawn S Badal; Farhad R Danesh
Related Documents :
11275265 - The role of hepatocytes in the clearance of liposomes from the blood circulation.
23307875 - Vascular function during prolonged progression and regression of atherosclerosis in mice.
2051905 - Clinicopathological study of lymphocyte attachment to endothelial cells (endothelialiti...
14633405 - A hemodynamic response to intravenous adenovirus vector particles is caused by systemic...
16775505 - Statins blunt thrombin-induced down-regulation of endothelial nitric oxide synthase exp...
23999965 - Comparative cryo-sem and afm studies of hylid and rhacophorid tree frog toe pads.
Publication Detail:
Type:  Comment; Journal Article    
Journal Detail:
Title:  Kidney international     Volume:  82     ISSN:  1523-1755     ISO Abbreviation:  Kidney Int.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-15     Completed Date:  2013-04-29     Revised Date:  2014-02-14    
Medline Journal Info:
Nlm Unique ID:  0323470     Medline TA:  Kidney Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1151-4     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Diabetes Mellitus, Experimental / enzymology*
Diabetic Nephropathies / enzymology*
Endothelium, Vascular / enzymology*
Kidney Glomerulus / enzymology*
Nitric Oxide Synthase Type III / metabolism*
Grant Support
ID/Acronym/Agency:
R01 DK078900/DK/NIDDK NIH HHS; R01 DK091310/DK/NIDDK NIH HHS; T32 GM088129/GM/NIGMS NIH HHS
Chemical
Reg. No./Substance:
EC 1.14.13.39/Nitric Oxide Synthase Type III; EC 1.14.13.39/Nos3 protein, mouse
Comments/Corrections
Comment On:
Kidney Int. 2012 Dec;82(11):1176-83   [PMID:  22785174 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Modulation of apoptosis by ischemic preconditioning: an emerging role for miR-21.
Next Document:  Lixivaptan: a vasopressin receptor antagonist for the treatment of hyponatremia.